ClinicalTrials.gg
RecruitingNCT07205536ANC-IIT-004Updated Dec 11, 2025

Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy

A Phase 2 interventional study of Mecapegfilgrastim injection and Oral or short-acting granulocyte-stimulating agents in Myelosuppression, Thoracic Neoplasms and Chemoradiotherapy, sponsored by Affiliated Hospital of Nantong University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Affiliated Hospital of Nantong University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Thoracic Neoplasms with a site in China — 8 open to participants now, 11 under way, 2 of them phase 3. Thoracic Neoplasms · China.

Planned enrollment
15th of 18
30 · median 173
Started
2025
with 2 others
Phase 2
5 of 23
3 open now
Primary completion
2027-12
later than 7 of 10 live
Registered
22nd of 23
by date
Lead sponsor
1 of 23
Affiliated Hospital of Nantong University

Among the 23 studies in Thoracic Neoplasms with a site in China, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 22nd registered.

Thoracic Neoplasms

115 studies on the registry are indexed under Thoracic Neoplasms; 30 are open to participants now.

Browse Thoracic Neoplasms studies →

Open to participants now

8 of the 23 studies in Thoracic Neoplasms with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Thoracic Neoplasms studies recruiting now, 18 (67%) set no upper age limit and 6 (22%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Thoracic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.

Read the detailed description

Group 1: Monitor the changes in neutrophil levels during the first follow-up cycle after enrollment in this study. When the neutrophil level falls below 1.5×10⁹/L, the investigator will communicate with the patient to determine whether to use conventional leukocyte-increasing drugs such as Licorice tablets. If so, the patient will be assigned to Group 1.

Group 2: After enrollment in this study, the investigator will communicate with the patient to determine whether to use Sulfated PEG-Interferon injection to prevent and treat neutropenia. If so, 24 hours after the end of the chemotherapy cycle, the patient will receive a subcutaneous injection of Sulfated PEG-Interferon once. The recommended dose is a fixed dose of 6 mg per injection; or, based on the patient's weight, an individualized treatment dose of 100 μg/kg. The patient will then be assigned to Group 2.

03

Conditions studied

  • Myelosuppression
  • Thoracic Neoplasms
  • Chemoradiotherapy

Keywords

  • Neutropenia
  • Febrile neutropenia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75 years at the time of giving , both sexes eligible
  • or cytologically confirmed thoracic tumor (esophageal or lung cancer)
  • Investigator judges the patient suitable for treatment with mecapegfilgrastim injection or leucogen tablets
  • Expected survival > 3 months
  • Signed informed consent; willing and able to comply with protocol-mandated visits
  • The patient is indicated for concurrent chemoradiotherapy and is currently/receiving or will receive a high-risk chemotherapy regimen for febrile neutropenia (FN risk ≥20%), or is currently/receiving or will receive an intermediate-risk chemotherapy regimen for FN (FN risk 10%\~20%) with additional FN risk factors.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Known to mecapegfilgrastim, pegylated or non-pegylated rhG-CSF, or any E. coli-derived product
  • Any severe comorbidity that, in the investigator's opinion, compromises patient safety or ability to complete the study
  • Any other condition that, in the investigator's judgment, could interfere with study conduct or interpretation of results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Oral or short-acting granulocyte-stimulating agents

    When the neutrophil count falls below 1.5 × 10⁹/L, the investigator will discuss with the patient whether to initiate standard granulocyte-boosting therapy such as leucogen tablets.

    Drug: Oral or short-acting granulocyte-stimulating agents

  • Experimental
    Mecapegfilgrastim injection

    Administer a single subcutaneous injection of mecapegfilgrastim 24 hours after the end of each chemotherapy cycle. The recommended dose is a fixed 6 mg, or individualised dosing at 100 μg/kg based on patient body weight.

    Drug: Mecapegfilgrastim injection

Interventions

  • DrugPegylated granulocyte colony-stimulating factorStudies of Pegylated granulocyte colony-stimulating factorPegylated granulocyte colony-stimulating factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After enrollment, a single subcutaneous dose of mecapegfilgrastim should be administered 24 hours following completion of each chemotherapy cycle. The recommended dose is a fixed 6 mg, or an individualized 100 μg/kg based on the patient's body weight. If neutrophil counts remain below 0.5 × 10⁹/L for more than 24 hours after mecapegfilgrastim administration, short-acting G-CSF may be used as rescue therapy at the investigator's discretion until neutrophil levels return to normal.

  • DrugOral or short-acting granulocyte-stimulating agents

    In the first cycle after enrollment, patients will be followed for changes in neutrophil counts. Should the neutrophil level fall below 1.5 × 10⁹/L, the investigator may, based on clinical judgment, decide whether to intervene with leucogen tablets or other granulocyte-boosting agents. If the count remains below 1.0 × 10⁹/L, short-acting G-CSF may be administered as a rescue therapy.

06

What researchers measure

Primary outcomes

  1. Incidence of hematologic toxicity

    Hematologic toxicity, assessed by CBC performed 1 day before chemotherapy and on days 7 and 14 post-chemotherapy; CBC may be done at an external facility.

    Time frame: Day 7,Day 14

Secondary outcomes

  1. The incidence of non-hematologic toxicity

    Secondary Outcome Measures: Non-hematologic toxicity On Day 1 of cycles 1 and 2: vital signs, complete blood count, urinalysis, stool routine, serum chemistry, coagulation panel, and 12-lead ECG. On Days 7 and 14 of cycles 1 and 2: repeat complete blood count only. All patient-reported adverse events are captured through 30 days after completion of radiotherapy.

    Time frame: Day 1, Day 7, and Day 14 of the first and second anti-tumor treatment cycles, and Day 30 after the completion of radiotherapy.

07

Study locations

1 of 1 sites recruiting
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 226001, China
    Recruiting
    • Zhiming Chen · Contact86+15851396885
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Oct 3, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07205536
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Aug 1, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 11, 2025

Study contacts

Zhiming CHEN
Contact
chenzhiming@ntu.edu.cn
86+15851396885

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegylated granulocyte colony-stimulating factor

Start the discussion